Epidermal growth factor receptor exon 20 mutation increased in post-chemotherapy patients with non-small cell lung cancer detected with patients' blood samples.
Explore this paper's citation graph
Summary
The data indicate that the chemotherapy may induce EGFR-TKI-resistant mutation in NSCLC cells and EGFR -TKI should be used in the early stage ofNSCLC but not after chemotherapy.
- Type
- article
- Published
- 2013-08-01
- Cited by
- 11
- References
- 44
- Access
- Open access
- OpenAlex
- https://openalex.org/W1972478091
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:21366947
Keywords
Exon, Epidermal growth factor receptor, Medicine, Lung cancer, Adenocarcinoma
References
- Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
- The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
- Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
- EGFR testing in lung cancer is ready for prime time.
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China
- Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
- Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study
- Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
- Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
- First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
- Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
- EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
- Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
- Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
- Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.
Cited by
- Influence of chemotherapy on EGFR mutation status.
- A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients
- Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
- Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation
- [Role of pretherapeutic biomarkers in lung cancer with special regards to bronchoscopic procedures].
- Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
- Targeted Hot Spot Sequencing of Uzbek Lung Cancer Patients
- Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.
- EGFR Q787Q Polymorphism Is a Germline Variant and a Prognostic Factor for Lung Cancer Treated With TKIs
- Evaluating the epidermal growth factor receptor in non small cell carcinoma of lung according to the grade of tumor and cellular differentiation
Related papers
- Detection of EGFR Mutations in Bronchial Wash from Iraqi patients with nonsmall Cell Lung Cancer (NSCLC)
- P2.13 Topic: Advanced NSCLC Frequency of Uncommon EGFR Mutations in CR
- [Exon 19 Deletion and Exon 21 L858R Point Mutation in EGFR Mutation‒Positive Non‒Small Cell Lung Cancer].
- An exon 19 mutation of EGFR gene in the serum circulating DNA from patients with advanced lung cancer
- EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis
- High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand.
- Uncommon V599E BRAF mutations in Japanese patients with lung cancer.